ANDA 212288, held by Alkem Laboratories. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 212288 (Methylphenidate Hydrochloride), held by Alkem Laboratories, was first approved by FDA on Oct 6, 2020, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylphenidate Hydrochloride20MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Sep 23, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 6, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters